Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Minimal residual disease response leading to better outcomes for patients with relapsed/refractory acute lymphoblastic leukemia after treatment with blinatumomab

Posted by on Dec 7, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab.   This study concluded that achieving minimal residual disease response leads to better outcomes for...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Evaluating measurable residual disease at myeloablative allogenic transplantation in patients with acute lymphoblastic leukemia

Posted by on Nov 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if measurable residual disease (MRD) before transplant in patients with acute lymphoblastic leukemia (ALL) is associated with different outcomes in patients undergoing myeloablative total body irradiation (TBI)-based and chemotherapy (CT)-based conditioning.  This study concluded that...

Read More

Outcomes for patients with acute myeloid leukemia who receive ex vivo T cell-depleted hematopoietic stem cell transplantation

Posted by on Nov 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of patients with acute myeloid leukemia after ex vivo T cell-depleted allogeneic hemopoietic stem cell transplant.   This study concluded that the outcomes for these patients compare favorably to an unmodified transplant and that the modified transplant leads to lower rates of...

Read More

Blinatumomab compared to standard of care treatment for patients with acute lymphoblastic leukemia

Posted by on Nov 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of blinatumomab treatment and standard of care treatment for patients with relapsed/unresponsive Philadelphia chromosome-positive acute lymphoblastic leukemia.  This study concluded that blinatumomab is a more suitable treatment for these patients than standard of care...

Read More

The effect of uric acid levels on the outcomes of patients having an allogeneic stem cell transplant

Posted by on Nov 2, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes. This study concluded that high uric acid levels before the transplant led to increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It can also be a...

Read More